Hematology

With vincristine in short supply, Teva will resume production of the chemotherapy agent following its previous decision to remove the product from the market.

Survivors of long-term diffuse large B-cell lymphoma found to have a higher risk of developing a second primary cancer.

A study looked at the incidence of thrombosis in patients being treated with ibrutinib for hematologic malignancies.

A phase 3 study evaluated ixazomib (Ninlaro, Takeda) in the first-line maintenance therapy setting for patients with multiple myeloma who have not undergone autologous stem cell transplant.

The ADMIRAL trial found that gilteritinib is a significant addition to the treatments available for patients with FLT3 mutation-positive relapsed or refractory acute myeloid leukemia.

Early treatment with lenalidomide in patients with smoldering multiple myeloma may help delay onset of myeloma-related bone and organ damage.

An ongoing phase 2 study is evaluating SY-1425 plus azacitadine in newly-diagnosed unfit patients with acute myeloid leukemia.

Patients with non-Hodgkin lymphoma were more likely to discontinue treatment early when prescribed rituximab by physicians who had less experience with the drug.

Bemcentinib is being evaluated as a treatment for elderly patients with acute myeloid leukemia whose disease has relapsed.

The high cost of treating blood cancer may contribute to delayed initiation of active treatment in newly-diagnosed Medicare beneficiaries.

Ravulizumab-cwvz (Ultomiris, Alexion) is indicated to inhibit complement-mediated thrombotic microangiopathy in adult and pediatric patients with atypical hemolytic uremic syndrome.

A phase 3 study assessed the efficacy and safety of plitidepsin (Aplidin) in combination with dexamethasone in patients with relapsed/refractory multiple myeloma.

Researchers find 4 genetic variants that are strongly associated with the risk of acute lymphoblastic leukemia in children with Down syndrome.

Study finds health-related quality of life is often not collected for novel cancer drugs when they are submitted for reimbursement.

Two cell mutations have been linked to acute myeloid leukemia, but the reason for their cooperation has been unknown.

Study shows the importance of a cancer-causing oncogene, known as SET/TAF1, in triggering cancer cell proliferation.

Daratumumab was approved based on results from part one of the Phase III CASSIOPEIA study.

Study indicated that patients who received radiation 30 days or fewer before their CAR T-cell infusion did not experience serious cytokine release syndrome or neurotoxicity.

Patients with diabetes demonstrated a higher likelihood of developing non-Hodgkin lymphoma than those without diabetes, especially among men.

Top news of the day from across the health care landscape.

Hematology and oncology pharmacists discussed patient outreach at a panel during the Hematology/Oncology Pharmacy Association’s (HOPA) annual conference in April.

A new study identified pathways that may serve as therapeutic targets for overcoming drug resistance in acute myeloid leukemia.

Immunotherapy methods emerged on the oncology market as adoptive cell transfers, specifically chimeric antigen receptor (CAR) T-cell therapies, with clear benefits in hematologic malignancy treatment.

On November 2018, the FDA approved Pfizer’s glasdegib (Daurismo) for the treatment of newly diagnosed acute myeloid leukemia (AML) in patients 75 years and older with comorbidities that prevent the use of intensive induction-dose chemotherapy.

The study findings suggest that, while the link between chronic lymphocytic leukemia and melanoma had been known, the rate at which the link occurs is higher than expected.

ABP 798, a biosimilar candidate to rituximab (Rituxan), demonstrated clinical equivalence in a study of patients with non-Hodgkin lymphoma.

Selinexor with dexamethasone effective in more than one-quarter of patients with multiple myeloma during a clinical trial.

Top news of the day from across the health care landscape.

Combination of ibrutinib and rituximab found to improve overall survival in patients with chronic lymphocytic leukemia.

Zanubrutinib, a Bruton’s tyrosine kinase inhibitor, is being evaluated in a broad pivotal clinical program across multiple B-cell malignancies.